Open AccessEffect of chidamide on treating hepatosplenic T-cell lymphoma: A case report
Author(s) -
Xingtong Wang,
Wei Guo,
Min Sun,
Wei Han,
Zhonghua Du,
Xiuxiu Wang,
Bowen Du,
Ou Bai
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i14.3122
Subject(s) - medicine , vincristine , cytarabine , cyclophosphamide , chemotherapy , regimen , lymphoma , splenectomy , gastroenterology , surgery , oncology , spleen
Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of non-Hodgkin's lymphoma, which has an aggressive clinical course and an extremely poor prognosis. Chidamide is a novel, orally active, benzamide-type histone deacetylase (HDAC) inhibitor that has been used for peripheral T-cell lymphoma (PTCL) treatment. However, to date, there has been no report of the treatment and effect of the HDAC inhibitor chidamide in HSTCL, which is a special subtype of PTCL.